Betahistin-SZ, tablets 24 mg 30 pcs

Pharmacodynamics

Betahistine acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the central nervous system. By means of direct agonistic (stimulating) influence on H1-receptors of the inner ear vessels and indirectly through the influence on H3-receptors it improves microcirculation and capillary permeability, normalizes the endolymph pressure in the cochlea and labyrinth. At the same time, betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of H3-receptor nuclei of the vestibular nerve. It improves conduction in neurons of vestibular nuclei at brainstem level.

Limits the frequency and intensity of dizziness, reduces tinnitus, improves hearing when it is reduced.

Stable therapeutic effect occurs after 14 days.

Pharmacokinetics

Absorbed completely after oral administration, binding to plasma proteins is low. Time to reach maximum concentration in blood plasma – 3 hours. It is almost completely eliminated by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours.

The elimination half-life is 3-4 hours.

Indications

The treatment of Meniere’s syndrome characterized by vertigo (accompanied by nausea and vomiting), decreased hearing and tinnitus.

The symptomatic treatment of vestibular vertigo (vertigo).

Active ingredient

Betahistine

Composition

Betahistine dihydrochloride – 24 mg

How to take, the dosage

Orally, with meals, 1 tablet (24mg) of Betahistine twice a day.

The dose of the drug and the duration of administration are chosen individually, depending on the patient’s response to therapy.

Emprovement of the condition is noticed at the beginning of the course of therapy; stable therapeutic effect comes after 2-3 weeks of therapy.

Interaction

Betahistine is a histamine analog, an interaction between betahistine and histamine receptor blockers could theoretically affect the effectiveness of one of these drugs.

Special Instructions

Therapeutic effect in a number of cases increases within a few months from the start of treatment.

Impact on the ability to drive, operate machinery

Possible decrease in the speed of psychomotor reactions, which reduces the ability to drive vehicles and operate precise mechanisms.

.

Contraindications

• Hypersensitivity to components of Betahistine,
• pheochromocytoma,
• pregnancy,
• lactation period,
• pregnant period.
• childhood,
• lactase deficiency,
• lactose intolerance,
• glucose-galactose malabsorption.

With caution: peptic ulcer or duodenal ulcer (history), bronchial asthma.

.

Side effects

Digestive system disorders: nausea, dyspepsia.

Nervous system disorders: headache.

Allergic reactions: hypersensitivity, including anaphylactic reactions.

Digestive system disorders: vomiting, abdominal pain, abdominal bloating.

Skin disorders: angioedema, urticaria, itching, rash.

.

Overdose

Symptoms: nausea, abdominal pain, drowsiness (when taken in dose up to 640 mg); convulsions, cardiopulmonary complications (when taken in dose more than 640 mg or in combination with other drugs).

Treatment: gastric lavage, activated charcoal, symptomatic therapy.

.

Pregnancy use

There are insufficient data to evaluate the possibility of using the drug during pregnancy and lactation. Therefore, administration of Betahistine in pregnancy is not recommended.

Breastfeeding should be stopped if administration of the drug is necessary during lactation.

Similarities

Betaserk, Vestibo, Betahistine, Betahistine NW, Tagista, Vertran